|
|||||
|
|
|
|
|
|
 |
|
 |
|
|
|||||||||||
| Track 1 | Overview of RCC |  |
|||||||||
| Track 2 | Genetic abnormalities, angiogenesis and the biology of RCC | |
|||||||||
| Track 3 | Incorporation of molecular signatures into the UCLA and Memorial staging systems | |
|||||||||
| Track 4 | Biologic rationale for the development of novel agents in the treatment of RCC | |
|||||||||
| Track 5 | Role of sunitinib and sorafenib in the treatment of good- and intermediate-risk RCC |
|
|||||||||
| Track 6 | The mTOR inhibitor temsirolimus for intermediate- or poor-prognosis RCC | |
|||||||||
| Track 7 | Clinical benefits and side effects of angiogenesis inhibition in RCC | |
|||||||||
| Track 8 | Clinical trial data on the anti-VEGF monoclonal antibody bevacizumab in RCC | |
|||||||||
| Track 9 | HIF-driven versus VEGF-driven pathways in poor- versus good-risk RCC and the selection of a treatment approach | |
|||||||||
| Track 10 | SELECT trial: Identification of molecular markers to predict benefit from interleukin-2 | |
|||||||||
| Track 11 | Clinical algorithm for the treatment of metastatic RCC | |
|||||||||
| Track 12 | Counseling patients about side effects and toxicities with the multikinase and mTOR inhibitors | |
|||||||||
| Track 13 | Hand-foot syndrome associated with sunitinib and sorafenib | |
|||||||||
| Track 14 | Potential differences in the hand-foot syndrome associated with fluoropyrimidines versus MKIs | |
|||||||||
| Track 15 | Combining targeted agents with “vertical and horizontal inhibition” strategies | |
|||||||||
| Track 16 | ASSURE (ECOG-E2805): Adjuvant sorafenib, sunitinib or placebo for intermediate- or high-risk RCC | |
|||||||||
| Track 17 | Role of novel targeted agents in the treatment of papillary RCC | |
|||||||||
|
|||||||||||
| Track 1 | Recent research developments regarding the biology of RCC | |
|||||||||
| Track 2 | Etiologic factors associated with RCC | |
|||||||||
| Track 3 | Biology of RCC and development of novel MKIs | |
|||||||||
| Track 4 | Development of bevacizumab for RCC | |
|||||||||
| Track 5 | Efficacy of the mTOR inhibitor temsirolimus in poor-risk RCC | |
|||||||||
| Track 6 | Development of a treatment algorithm for RCC and overcoming resistance to MKIs |
|
|||||||||
| Track 7 | Selection of patients most likely to benefit from interleukin-2 | |
|||||||||
| Track 8 | Combination therapy strategies in RCC | |
|||||||||
| Track 9 | Identification of clinical predictors of response to therapeutic agents in RCC | |
|||||||||
| Track 10 | Sequencing agents in the treatment of RCC | |
|||||||||
| Track 11 | Side effects of agents blocking the VEGF pathway | |
|||||||||
| Track 12 | Dose and dose escalation strategies with sunitinib and sorafenib | |
|||||||||
| Track 13 | Side effects of sunitinib and sorafenib | |
|||||||||
| Track 14 | Importance of the initial treatment selection in RCC | |
|||||||||
| Track 15 | Selection of patients for treatment with interleukin-2 | |
|||||||||
| Track 16 | Counseling patients to minimize side effects and optimize therapeutic delivery of novel agents in RCC | |
|||||||||
| Track 17 | Temsirolimus-associated side effects and toxicity | |
|||||||||
| Track 18 | Safety of MKIs in the treatment of CNS metastases | |
|||||||||
| Track 19 | Cytoreductive nephrectomy in patients with RCC | |
|||||||||
| Track 20 | Challenges in completing adjuvant trials in RCC | |
|||||||||
 |
Terms of Use and General Disclaimer. | Privacy Policy Copyright © 2007 Research To Practice. All Rights Reserved. |
 |
